
Ovid Therapeutics Inc.
NASDAQ:OVID
Overview | Financials
Company Name | Ovid Therapeutics Inc. |
Symbol | OVID |
Currency | USD |
Price | 0.5 |
Market Cap | 35,504,950 |
Dividend Yield | 0% |
52-week-range | 0.463 - 3.45 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir |
Website | https://www.ovidrx.com |
An error occurred while fetching data.
About Ovid Therapeutics Inc.
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD